Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 428

1.

The state of dietary supplement adverse event reporting in the United States.

Gardiner P, Sarma DN, Low Dog T, Barrett ML, Chavez ML, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):962-70. doi: 10.1002/pds.1627. Review.

PMID:
18613260
2.

United States pharmacopeia safety evaluation of spirulina.

Marles RJ, Barrett ML, Barnes J, Chavez ML, Gardiner P, Ko R, Mahady GB, Low Dog T, Sarma ND, Giancaspro GI, Sharaf M, Griffiths J.

Crit Rev Food Sci Nutr. 2011 Aug;51(7):593-604. doi: 10.1080/10408391003721719. Review.

PMID:
21793723
3.

Adverse event monitoring and multivitamin-multimineral dietary supplements.

Woo JJ.

Am J Clin Nutr. 2007 Jan;85(1):323S-324S. Review.

4.

FDA regulation of dietary supplements and requirements regarding adverse event reporting.

Frankos VH, Street DA, O'Neill RK.

Clin Pharmacol Ther. 2010 Feb;87(2):239-44. doi: 10.1038/clpt.2009.263. Epub 2009 Dec 23.

PMID:
20032973
5.
6.

Dietary supplement adverse event reports: review and analysis.

Talati AR, Gurnani AK.

Food Drug Law J. 2009;64(3):503-13.

PMID:
19999641
7.

Role of US poison centers in adverse drug reactions monitoring.

Chyka PA.

Vet Hum Toxicol. 1999 Dec;41(6):400-2.

PMID:
10592954
8.

Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.

Johann-Liang R, Wyeth J, Chen M, Cope JU.

Pharmacoepidemiol Drug Saf. 2009 Jan;18(1):24-7. doi: 10.1002/pds.1679.

PMID:
19009550
9.

Physicians' understanding of the regulation of dietary supplements.

Ashar BH, Rice TN, Sisson SD.

Arch Intern Med. 2007 May 14;167(9):966-9.

PMID:
17502539
10.

Dietary supplement adverse events: report of a one-year poison center surveillance project.

Haller C, Kearney T, Bent S, Ko R, Benowitz N, Olson K.

J Med Toxicol. 2008 Jun;4(2):84-92.

11.

An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.

Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J, Avigan M.

Pharmacoepidemiol Drug Saf. 2008 Nov;17(11):1068-76. doi: 10.1002/pds.1643.

PMID:
18821724
12.
13.

The role of databases in drug postmarketing surveillance.

Rodriguez EM, Staffa JA, Graham DJ.

Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):407-10.

PMID:
11802586
14.

Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.

McAdams M, Staffa J, Dal Pan G.

Pharmacoepidemiol Drug Saf. 2008 Mar;17(3):229-39. doi: 10.1002/pds.1535.

PMID:
18175291
15.

Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).

DuMouchel W, Fram D, Yang X, Mahmoud RA, Grogg AL, Engelhart L, Ramaswamy K.

Ann Clin Psychiatry. 2008 Jan-Mar;20(1):21-31. doi: 10.1080/10401230701844612.

PMID:
18297583
16.

Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.

Clark JA, Humphries JE, Crean S, Reynolds MW.

Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):107-14. doi: 10.1002/pds.1874. Review.

PMID:
20014051
17.
18.

United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.

Mahady GB, Low Dog T, Barrett ML, Chavez ML, Gardiner P, Ko R, Marles RJ, Pellicore LS, Giancaspro GI, Sarma DN.

Menopause. 2008 Jul-Aug;15(4 Pt 1):628-38. doi: 10.1097/gme.0b013e31816054bf. Review.

PMID:
18340277
19.

Reporting of adverse events to MedWatch.

Piazza-Hepp TD, Kennedy DL.

Am J Health Syst Pharm. 1995 Jul 1;52(13):1436-9.

PMID:
7671043
20.

Dietary supplement-related adverse events reported to the California Poison Control System.

Dennehy CE, Tsourounis C, Horn AJ.

Am J Health Syst Pharm. 2005 Jul 15;62(14):1476-82.

PMID:
15998927

Supplemental Content

Support Center